FILING ANALYSIS · THURSDAY, OCTOBER 29
Phathom Pharmaceuticals, Inc. PHAT — 8-K: Results of Operations and Financial Condition
positive
Phathom Pharmaceuticals reported a 71% year-over-year increase in Q3 2026 net revenues to $84.7 million and generated positive operating cash flow for the second consecutive quarter, also reaffirming full-year 2026 financial guidance.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →